Please login to the form below

Not currently logged in
Email:
Password:

Intuniv

This page shows the latest Intuniv news and features for those working in and with pharma, biotech and healthcare.

Shire separates out neuroscience as it considers its future

Shire separates out neuroscience as it considers its future

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the

Latest news

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    Shire also has a foot in the non-stimulant camp with Intuniv (guanfacine), which was approved in Europe in September having been available in the US for some time - long enough

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics